INTERNATIONAL PATENT: COMPASS THERAPEUTICS, INC. FILES APPLICATION FOR "COMBINATION OF ANTIBODIES TARGETING DLL4/VEGF AND CD137 AGONISTS OR ANTI-PD1/ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER"

GENEVA, Oct. 15 -- COMPASS THERAPEUTICS, INC. (80 Guest StreetSuite 601Boston, Massachusetts 02135) filed a patent application (PCT/US2025/022664) for "COMBINATION OF ANTIBODIES TARGETING DLL4/VEGF AND CD137 AGONISTS OR ANTI-PD1/ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER" on Apr 02, 2025. With publication no. WO/2025/212726, the details related to the patent application was published on Oct 09, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ALBU, Diana (c/o Compass Therapeutics, Inc.80 Guest Street, Suite 601Boston, Massachusetts 02135), ULUMBEN, Amy Daniel (c/o Compass Therapeutics,...